tripropylene glycol diacrylate: a component of UV-Cured Lacquer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 4128060 |
CHEMBL ID | 2145379 |
SCHEMBL ID | 93458 |
MeSH ID | M0275906 |
Synonym |
---|
tripropylene glycol diacrylate |
NCGC00164105-01 |
42978-66-5 |
2-{2-[2-(acryloyloxy)-1-methylethoxy]-1-methylethoxy}-1-methylethyl acrylate |
trpgda |
FT-0639821 |
2-[2-(2-prop-2-enoyloxypropoxy)propoxy]propyl prop-2-enoate |
dtxsid7028015 , |
dtxcid108015 |
tox21_301282 |
cas-42978-66-5 |
NCGC00255375-01 |
vfm08chc4d , |
unii-vfm08chc4d |
1,4,7-trimethyl-3,6-dioxaoctamethylene diacrylate |
2-propenoic acid, 1-methyl-2-(1-methyl-2-(1-methyl-2-((1-oxo-2-propen-1-yl)oxy)ethoxy)ethoxy)ethyl ester |
94120-00-0 |
AKOS025311140 |
SCHEMBL93458 |
CHEMBL2145379 |
tri(propyleneglycol)diacrylate |
W-106250 , |
mfcd00064598 |
tripropylene glycol diacrylate, (stabilized with mehq) |
tri(propylene glycol) diacrylate |
AS-12342 |
1-(1-(1-(acryloyloxy)propan-2-yloxy)propan-2-yloxy)propan-2-yl acrylate |
Q27291809 |
1-((1-((1-(acryloyloxy)propan-2-yl)oxy)propan-2-yl)oxy)propan-2-yl acrylate |
A854586 |
1-((1-((1-(acryloyloxy)propan-2-yl)oxy)propan-2-yl)oxy)propan-2-ylacrylate |
F71246 |
tri(propylene glycol) diacrylate, mixture of isomers |
Excerpt | Reference | Relevance |
---|---|---|
" Quantities of TPGDA recovered from two consecutive tape strippings accounted for all of the test agent, demonstrating both the efficiency of the method to measure dermal exposure and the potential to determine the rate of absorption with successive samples over time." | ( A tape-stripping method for measuring dermal exposure to multifunctional acrylates. Nylander-French, LA, 2000) | 0.31 |
Excerpt | Relevance | Reference |
---|---|---|
" Based on dose-related increases in skin hyperplasia following dermal exposure to EA, TPGDA, or Lacquer A (applied equimolar for TPGDA concentration), the dosing regimen was selected." | ( Tripropylene glycol diacrylate but not ethyl acrylate induces skin tumors in a twenty-week short-term tumorigenesis study in Tg.AC (v-Ha-ras) mice. French, JE; Nylander-French, LA, ) | 1.57 |
" Viability of the cells after 2-24-h exposure to the representative monofunctional or multifunctional acrylate or solvent control was used to calculate an index of acute cytotoxicity (50% inhibitory dose; ID50) and to determine the shape of the dose-response curves." | ( Comparative in vitro cytotoxicity of ethyl acrylate and tripropylene glycol diacrylate to normal human skin and lung cells. French, JE; Nylander-French, LA, 2000) | 0.55 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 56.0157 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 30.6379 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 9.1617 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 49.7092 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 61.1306 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 72.6538 | 0.0010 | 22.6508 | 76.6163 | AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 43.6412 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 47.2165 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 47.6790 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 23.1546 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 55.3055 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 31.4655 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 55.3055 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743215 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 45.6141 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 58.6366 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223; AID743241 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 43.2771 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 8.7076 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 103.6990 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 24.3365 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 24.3365 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 31.2972 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 24.1054 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 29.7809 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743219 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 19.3312 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 15.3553 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 19.3312 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 34.6533 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
Ataxin-2 | Homo sapiens (human) | Potency | 24.3365 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 5 (55.56) | 29.6817 |
2010's | 1 (11.11) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.16) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (10.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (10.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |